Form 4: Tandem Diabetes Care CEO John F. Sheridan Reports Stock Transactions
SEC Form 4 Filing
John F. Sheridan, President and CEO of Tandem Diabetes Care, reports acquisition and disposal of company stock and restricted stock units on May 15, 2025.
Summary
- On May 15, 2025, John F. Sheridan, the President and CEO of Tandem Diabetes Care, reported transactions involving the company's stock.
- These transactions included the acquisition of common stock through the Employee Stock Purchase Plan (ESPP) and the vesting of restricted stock units (RSUs).
- Shares were also withheld to cover tax obligations related to the vesting of RSUs.
- The reported transactions resulted in a net increase in Sheridan's beneficial ownership of Tandem Diabetes Care common stock, bringing the total to 96,327 shares.
- Sheridan also holds a number of restricted stock units that will vest over time.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports stock transactions, which are a normal part of executive compensation. There is no indication of positive or negative sentiment.
Positives
- The CEO's participation in the ESPP demonstrates confidence in the company's future.
- The vesting of RSUs is part of a pre-determined compensation plan, aligning executive interests with shareholder value.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the medical device industry.
- Companies like Insulet and Dexcom also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules and terms of Tandem's RSUs appear to be in line with industry norms.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- However, they provide transparency into executive compensation and alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 05/18/2021 | Date of RSU award pursuant to the 2013 Stock Incentive Plan. |
| 05/25/2022 | Date of RSU award pursuant to the 2013 Stock Incentive Plan. |
| 05/25/2023 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan. |
| 05/23/2024 | Date of RSU award pursuant to the 2023 Long-Term Incentive Plan. |
| 05/15/2025 | Date of reported transactions, including stock acquisitions and RSU vesting. |
| 05/19/2025 | Date of Form 4 signature. |
Keywords
Tandem Diabetes Care, TNDM, John F. Sheridan, Stock Transactions, Form 4, Restricted Stock Units, Employee Stock Purchase Plan, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.